12:00 AM
 | 
Jul 29, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

PUR0200: Phase Ib started

Pulmatrix began a placebo-controlled, 5-way crossover, U.K. Phase Ib trial of PUR0200 in up to 60 patients with moderate COPD.

Read the full 83 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >